AKT1 and cancer: Furthermore, we found that niclosamide not only inhibits STAT3 and Wnt/β-catenin signaling, which has been seen in other cancer cells, but it also down-regulates two other pro-survival signal pathways (PI3K/AKT and MAPK/ERK) in these cells.